Labiana Health (XMAD:LAB) Debt-to-Asset : 0.63 (As of Dec. 2022)

View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Debt-to-Asset?

Labiana Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was €20.01 Mil. Labiana Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was €18.19 Mil. Labiana Health's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2022 was €60.78 Mil. Labiana Health's debt to asset for the quarter that ended in Dec. 2022 was 0.63.

Labiana Health Debt-to-Asset Historical Data

The historical data trend for Labiana Health's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Debt-to-Asset Chart

Labiana Health Annual Data

Trend

Dec20

Dec21

Dec22

Debt-to-Asset

0.59

0.66

0.63

Labiana Health Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22
Debt-to-Asset	0.59	0.66	0.58	0.63

Competitive Comparison of Labiana Health's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Labiana Health's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Labiana Health's Debt-to-Asset falls into.

Labiana Health Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Labiana Health's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(20.008	+	18.189)	/	60.779
	=	0.63

Labiana Health's Debt-to-Asset for the quarter that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(20.008	+	18.189)	/	60.779
	=	0.63

Labiana Health (XMAD:LAB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Labiana Health Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Labiana Health's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Labiana Health (XMAD:LAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Debt-to-Asset

Traded in Other Exchanges

N/A

Address

Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023

Website

https://www.labiana.com

Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.